The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B

[Guest guest]

http://www.docguide.com/effects-pegylated-interferon-lamivudine-therapy-auditory\

-functions-patients-chronic-hepatitis-b?tsid=5

Source: Auris Nasus Larynx | Posted 1 week ago

The effects of pegylated interferon/lamivudine therapy on auditory functions in

patients with chronic hepatitis B

Eser Karlidag G, Karlidag, T, Demirdag K, Keles E; Auris Nasus Larynx (Jan 2011)

OBJECTIVES: The aim of this study was to assess the effects of pegylated

interferon monotherapy and pegylated interferon+lamivudine combination therapy

on auditory functions in patients with chronic hepatitis B (CHB) infection.

METHODS: A total of 54 patients with a diagnosis of CHB were grouped into four

treatment groups: patients in Group 1 received pegylated interferon-alpha 2a;

patients in Group 2 received pegylated interferon-alpha 2a+lamivudine; patients

in Group 3 received pegylated interferon-alpha 2b, and patients in Group 4

received pegylated interferon-alpha 2b+lamivudine treatment. The auditory system

(using standard and high frequency audiometry) and the vestibulocochlear adverse

effects including otalgia, tinnitus, vertigo and imbalance were assessed

immediately before the onset of the study, and at the 12th, 24th, and 48th weeks

of the study. RESULTS: A mean elevation of auditory threshold of 1-10dB was

found in all treatment groups when the thresholds at the onset of the study and

the thresholds at the 12th, 24th, and 48th weeks were compared. However, the

elevations were not significant. The elevations were mostly at high frequencies

(10,000, 12,000 and 16,000Hz). The most common vestibulocochlear adverse effects

related to treatment were tinnitus, vertigo, imbalance, and otalgia,

respectively. Tinnitus was the most common adverse effect in Group 2, vertigo

was the most common in Group 3, imbalance was at equal frequency in Group 2 and

3, and otalgia was the most common adverse effect in Group 2 (p>0.05).

CONCLUSION: There were no significant auditory adverse effects in the treatment

groups. We think that it may be beneficial to monitor the auditory functions in

patients receiving PEG-IFN treatment because of the mild elevation in the

auditory thresholds (although not significant).

[Guest guest]

http://www.docguide.com/effects-pegylated-interferon-lamivudine-therapy-auditory\

-functions-patients-chronic-hepatitis-b?tsid=5

Source: Auris Nasus Larynx | Posted 1 week ago

The effects of pegylated interferon/lamivudine therapy on auditory functions in

patients with chronic hepatitis B

Eser Karlidag G, Karlidag, T, Demirdag K, Keles E; Auris Nasus Larynx (Jan 2011)

OBJECTIVES: The aim of this study was to assess the effects of pegylated

interferon monotherapy and pegylated interferon+lamivudine combination therapy

on auditory functions in patients with chronic hepatitis B (CHB) infection.

METHODS: A total of 54 patients with a diagnosis of CHB were grouped into four

treatment groups: patients in Group 1 received pegylated interferon-alpha 2a;

patients in Group 2 received pegylated interferon-alpha 2a+lamivudine; patients

in Group 3 received pegylated interferon-alpha 2b, and patients in Group 4

received pegylated interferon-alpha 2b+lamivudine treatment. The auditory system

(using standard and high frequency audiometry) and the vestibulocochlear adverse

effects including otalgia, tinnitus, vertigo and imbalance were assessed

immediately before the onset of the study, and at the 12th, 24th, and 48th weeks

of the study. RESULTS: A mean elevation of auditory threshold of 1-10dB was

found in all treatment groups when the thresholds at the onset of the study and

the thresholds at the 12th, 24th, and 48th weeks were compared. However, the

elevations were not significant. The elevations were mostly at high frequencies

(10,000, 12,000 and 16,000Hz). The most common vestibulocochlear adverse effects

related to treatment were tinnitus, vertigo, imbalance, and otalgia,

respectively. Tinnitus was the most common adverse effect in Group 2, vertigo

was the most common in Group 3, imbalance was at equal frequency in Group 2 and

3, and otalgia was the most common adverse effect in Group 2 (p>0.05).

CONCLUSION: There were no significant auditory adverse effects in the treatment

groups. We think that it may be beneficial to monitor the auditory functions in

patients receiving PEG-IFN treatment because of the mild elevation in the

auditory thresholds (although not significant).